Infensa Bioscience
Biotechnology ResearchView the employees at
Infensa Bioscience-
Ming Chong Leader in strategic planning and project implementation in Product Development, Technology Transfer and Manufacturing Operations
-
Melbourne, Victoria, Australia
-
Top 5%
Glenn King NHMRC Principal Research Fellow-
Brisbane, Queensland, Australia
-
Top 5%
Mark Smythe Chief Executive Officer-
Top 5%
Natalie Saez Researcher at IMB, UQ-
Greater Brisbane Area
-
Rising Star
Louisa Carey Chief Operating Officer and Company Secretary-
Canobolas, New South Wales, Australia
-
Top 5%
Overview
First-in-class drugs with addressable worldwide market of tens of millions of patients per year who suffer heart attack or stroke. Ability of a single drug class to address multiple diseases enables staged clinical development with continuous value creation. Other potential indications: traumatic head injury, hypoxic brain injury (cerebral palsy), retinal artery thrombosis, kidney artery thrombosis, cardiac and brain surgery, endarterectomy and heart valve replacement. Key asset protected by patents granted globally.
-